SCHEMBL3345127

SCHEMBL3345127

O=C(O)[C@@H](CS)N(Cl)Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30289991 0.77 KDM4E (0.38)
SCHEMBL4317322 0.76
SCHEMBL3382388 0.76
SCHEMBL3382387 0.76
SCHEMBL3315313 0.76
SCHEMBL7528412 0.76
SCHEMBL3315309 0.76
SCHEMBL22383997 0.75 ENPEP (0.39)
SCHEMBL3513292 0.74 PTGS1 (0.40)
SCHEMBL11711858 0.74 GPR84 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008090534-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF EXCESSIVE WEIGHT GAIN, REDUCTION OF INAPPROPRIATE EATING BEHAVIOURS AND INHIBITION OF BINGE EATING FOR THE TREATMENT OF OBESITY BERAND LIMITED (IE) 2008-07-31 WO claimed
WO-2007049262-A1 Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders BERAND LIMITED (IE) 2007-05-03 WO claimed
EP-4397970-A2 MUTANT PORE Oxford Nanopore Technologies PLC (GB) 2024-07-10 EP disclosed
EP-4122949-B1 MUTANT PORE OXFORD NANOPORE TECH PLC (GB) 2024-06-05 EP disclosed
WO-2024094986-A1 METHOD OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2024-05-10 WO disclosed
US-11939359-B2 Mutant pore OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2024-03-26 US disclosed
US-20240076729-A9 METHOD OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2024-03-07 US disclosed
US-11920193-B2 Method of characterizing a polynucleotide OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2024-03-05 US disclosed
US-20240044865-A1 METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2024-02-08 US disclosed
US-20230408408-A1 METHOD OF DETECTING AN ANALYTE IN A MEDIUM COMPRISING A LIGHT SCATTERING CONSTITUENT KING'S COLLEGE LONDON (GB) 2023-12-21 US disclosed
WO-2023222657-A1 METHOD AND ADAPTORS OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2023-11-23 WO disclosed
WO-2008053484-A2 PREPARATION OF HEAVY METAL-CONTAINING NANO-LIPOSOMES AND THEIR USES IN MEDICAL THERAPY S.B. BIOTECHNOLOGIES LTD. (IL) 2008-05-08 WO disclosed
WO-2008001109-A2 METHOD OF COVALENTLY LINKING A CARBOHYDRATE OR POLYALKYLENE OXIDE TO A PEPTIDE, PRECURSORS FOR USE IN THE METHOD AND RESULTANT PRODUCTS UCL BUSINESS PLC (GB) 2008-01-03 WO disclosed
WO-2007049262-A1 Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders BERAND LIMITED (IE) 2007-05-03 WO disclosed
US-20070087446-A1 Aromatic phosphonium salts and their use as labeling reagents in mass spectrometry analysis WATERS INVESTMENTS LIMITED (US) 2007-04-19 US disclosed
WO-2004092707-A2 AROMATIC PHOSPHONIUM SALTS AND THEIR USE AS LABELING REAGENTS MASS SPECTROMETRY ANALYSIS WATERS INVESTMENTS LIMITED (US) 2004-10-28 WO disclosed
US-6022522-A DETECTABLY LABELED BICONJUGATE COMPOUND WHICH COMPRISES A MONOCLONAL ANTIBODY AND A TECHTINIUM-99M COUPLED TO A CHELATING AGENT HAVING A RIGID CYCLIC HYDROCARBON BACKBONE OF GIVEN FORMULA, COUPLED TO THE MONOCLONAL ANTIBODY BROOKHAVEN SCIENCE ASSOCIATES (US) 2000-02-08 US disclosed
US-5783169-A RADIOIMMUNOCONJUGATED; DIAGNOSTIC AND THERAPY BROOKHAVEN SCIENCE ASSOCIATES LLC (US) 1998-07-21 US disclosed
US-4663481-A BROMINATION IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1987-05-05 US disclosed
EP-0144177-A1 Preparation of bromoacetamides IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1985-06-12 EP disclosed